Heartflow vs Travere Therapeutics

Heartflow (HTFL), health care, and Travere Therapeutics (TVTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Travere Therapeutics is worth $4.9B on the stock market and Heartflow $4.1B: Travere Therapeutics is valued at 19% more. Heartflow's operating margin in its latest fiscal year was -36.4% and Travere Therapeutics's -12.8%. Over the past year Heartflow's share price has moved +71.6% and Travere Therapeutics's +38.1%.

Key facts

Heartflow market value
$4.1B
Travere Therapeutics market value
$4.9B
Heartflow P/E
70.3
Heartflow revenue
$176MFY to 2025-12-31
Travere Therapeutics revenue
$490.7MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Heartflow vs Travere Therapeutics: every measure side by side
Measure Heartflow Travere Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.1Blower$4.9Bhigher
Revenue$176Mlower$490.7Mhigher
Earnings-$116.8Mlower-$25.5Mhigher
Employees843higher497lower
Total assets$359.5Mlower$605.2Mhigher
Valuation
P/E70.3—
P/S23.5higher10.0lower
P/B14.6lower217higher
Dividend yield0.00%0.00%
Profitability
Operating margin-36.4%lower-12.8%higher
Balance sheet
Net assets$300.6Mhigher$114.8Mlower
Total liabilities$58.8Mlower$490.4Mhigher
Total debt——
Cash on hand$44.8Mlower$93Mhigher
Price change
Today+0.45%lower+2.82%higher
1 year+71.6%higher+38.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Heartflow only (2)

Travere Therapeutics only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Heartflow / Travere Therapeutics). Who owns HTFL · Who owns TVTX

Further comparisons

Learn

Questions and answers

Which is bigger, Heartflow or Travere Therapeutics?

By market value, Travere Therapeutics is the larger: $4.9B against $4.1B for Heartflow. By revenue in its latest fiscal year, Travere Therapeutics is the larger: $490.7M against $176M for Heartflow.

Which has the higher operating margin?

Travere Therapeutics: -12.8%, against -36.4% for Heartflow. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Heartflow and Travere Therapeutics?

In their latest 13F filings, Polen Capital team holds both.

Cite this page

Funkfolio, “Heartflow vs Travere Therapeutics”, data as of 17 November 2026. https://funkfolio.com/compare/htfl-vs-tvtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.